Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Zhongxing Liao MD
Open to Accrual
To compare the overall survival (OS) in patients with stage II-IIIB NSCLC after image guided, motion-managed photon radiotherapy (Arm 1) or after image guided, motion-managed proton radiotherapy (Arm 2) both given with concurrent platinum- based chemotherapy.
Untreated histologically or cytologically proven diagnosis of non-small cell lung cancer prior to registration. Clinical AJCC (7th ed.) stage II-IIIB medically non-operable disease, or surgically unresectable disease, or patients who refuse surgery; patients who present with N2 or N3 disease and an undetectable NSCLC primary tumor also are eligible.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.